JP2019512464A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2019512464A5 JP2019512464A5 JP2018543153A JP2018543153A JP2019512464A5 JP 2019512464 A5 JP2019512464 A5 JP 2019512464A5 JP 2018543153 A JP2018543153 A JP 2018543153A JP 2018543153 A JP2018543153 A JP 2018543153A JP 2019512464 A5 JP2019512464 A5 JP 2019512464A5
- Authority
- JP
- Japan
- Prior art keywords
- antibody
- seq
- chain variable
- variable region
- heavy chain
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
Priority Applications (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP2022030779A JP2022069488A (ja) | 2016-02-17 | 2022-03-01 | 癌及び免疫学的障害を治療するためのｂｃｍａ抗生物質及びその使用 |
| JP2023216464A JP2024019677A (ja) | 2016-02-17 | 2023-12-22 | 癌及び免疫学的障害を治療するためのｂｃｍａ抗生物質及びその使用 |
Applications Claiming Priority (5)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201662296594P | 2016-02-17 | 2016-02-17 | |
| US62/296,594 | 2016-02-17 | ||
| US201662396084P | 2016-09-16 | 2016-09-16 | |
| US62/396,084 | 2016-09-16 | ||
| PCT/US2017/018177 WO2017143069A1 (en) | 2016-02-17 | 2017-02-16 | Bcma antibodies and use of same to treat cancer and immunological disorders |
Related Child Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2020024261A Division JP2020073605A (ja) | 2016-02-17 | 2020-02-17 | 癌及び免疫学的障害を治療するためのｂｃｍａ抗生物質及びその使用 |
| JP2022030779A Division JP2022069488A (ja) | 2016-02-17 | 2022-03-01 | 癌及び免疫学的障害を治療するためのｂｃｍａ抗生物質及びその使用 |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2019512464A JP2019512464A (ja) | 2019-05-16 |
| JP2019512464A5 true JP2019512464A5 (enExample) | 2020-03-26 |
| JP7152309B2 JP7152309B2 (ja) | 2022-10-12 |
Family
ID=59562012
Family Applications (4)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2018543153A Active JP7152309B2 (ja) | 2016-02-17 | 2017-02-16 | 癌及び免疫学的障害を治療するためのｂｃｍａ抗生物質及びその使用 |
| JP2020024261A Pending JP2020073605A (ja) | 2016-02-17 | 2020-02-17 | 癌及び免疫学的障害を治療するためのｂｃｍａ抗生物質及びその使用 |
| JP2022030779A Withdrawn JP2022069488A (ja) | 2016-02-17 | 2022-03-01 | 癌及び免疫学的障害を治療するためのｂｃｍａ抗生物質及びその使用 |
| JP2023216464A Pending JP2024019677A (ja) | 2016-02-17 | 2023-12-22 | 癌及び免疫学的障害を治療するためのｂｃｍａ抗生物質及びその使用 |
Family Applications After (3)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2020024261A Pending JP2020073605A (ja) | 2016-02-17 | 2020-02-17 | 癌及び免疫学的障害を治療するためのｂｃｍａ抗生物質及びその使用 |
| JP2022030779A Withdrawn JP2022069488A (ja) | 2016-02-17 | 2022-03-01 | 癌及び免疫学的障害を治療するためのｂｃｍａ抗生物質及びその使用 |
| JP2023216464A Pending JP2024019677A (ja) | 2016-02-17 | 2023-12-22 | 癌及び免疫学的障害を治療するためのｂｃｍａ抗生物質及びその使用 |
Country Status (14)
| Country | Link |
|---|---|
| US (6) | US20170233484A1 (enExample) |
| EP (1) | EP3416687A4 (enExample) |
| JP (4) | JP7152309B2 (enExample) |
| KR (1) | KR102816905B1 (enExample) |
| CN (2) | CN108778329B (enExample) |
| AU (2) | AU2017219747B2 (enExample) |
| BR (1) | BR112018016697A2 (enExample) |
| CA (1) | CA3011900A1 (enExample) |
| HK (1) | HK1259075A1 (enExample) |
| IL (2) | IL260732B2 (enExample) |
| MA (1) | MA44254A (enExample) |
| MX (2) | MX2018009700A (enExample) |
| SG (2) | SG10202007836WA (enExample) |
| WO (1) | WO2017143069A1 (enExample) |
Families Citing this family (47)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| MA44254A (fr) | 2016-02-17 | 2018-12-26 | Seattle Genetics Inc | Anticorps bcma et leur utilisation pour traiter le cancer et les troubles immunologiques |
| US11166985B2 (en) | 2017-05-12 | 2021-11-09 | Crispr Therapeutics Ag | Materials and methods for engineering cells and uses thereof in immuno-oncology |
| BR112019023608A2 (pt) | 2017-05-12 | 2020-05-26 | Crispr Therapeutics Ag | Materiais e métodos para células manipuladas e seus usos em imuno-oncologia |
| US20200063100A1 (en) | 2018-05-11 | 2020-02-27 | Crispr Therapeutics Ag | Methods and compositions for treating cancer |
| WO2020004937A1 (ko) * | 2018-06-26 | 2020-01-02 | 주식회사 티에스디라이프사이언스 | 항-bcma 항체-약물 접합체 및 그 용도 |
| TWI838389B (zh) | 2018-07-19 | 2024-04-11 | 美商再生元醫藥公司 | 雙特異性抗-BCMAｘ抗-CD3抗體及其用途 |
| LT4324851T (lt) | 2018-07-19 | 2025-10-10 | Chimeriniai antigeno receptoriai, pasižymintys bcma specifiškumu, ir jų panaudojimas | |
| EP4578507A3 (en) | 2018-11-01 | 2025-11-12 | Gracell Biotechnologies (Shanghai) Co., Ltd. | Compositions and methods for t cell engineering |
| CA3123591A1 (en) * | 2018-12-19 | 2020-06-25 | Seagen Inc. | Controlled fucosylation of antibodies |
| KR20210133261A (ko) * | 2019-02-26 | 2021-11-05 | 소렌토 쎄라퓨틱스, 인코포레이티드 | Bcma에 결합하는 항원 결합 단백질 |
| KR20210143246A (ko) | 2019-03-21 | 2021-11-26 | 리제너론 파아마슈티컬스, 인크. | 알레르기 치료용 il-4/il-13 경로 억제제 및 형질 세포 절제의 병용 |
| CA3138633A1 (en) | 2019-04-30 | 2020-11-05 | Crispr Therapeutics Ag | Allogeneic cell therapy of b cell malignancies using genetically engineered t cells targeting cd19 |
| EP4778585A2 (en) * | 2019-05-07 | 2026-07-22 | Gracell Bioscience (Shanghai) Co., Ltd. | Engineered immune cell targeting bcma and use thereof |
| CA3140762A1 (en) * | 2019-05-31 | 2020-12-03 | Medimmune, Llc | Combination therapy |
| BR112022001546A2 (pt) * | 2019-07-30 | 2022-03-22 | Jiangsu Hansoh Pharmaceutical Group Co Ltd | Anticorpo anti-bcma, fragmento de ligação ao antígeno do mesmo e uso médico do mesmo |
| CN112409482B (zh) * | 2019-08-20 | 2022-08-26 | 杭州尚健生物技术有限公司 | Bcma抗体 |
| CN120775052A (zh) * | 2019-10-10 | 2025-10-14 | 再凌生物医药(香港)有限公司 | 靶向bcma的具有人猴交叉的人源化单克隆抗体 |
| AU2020382219A1 (en) | 2019-11-13 | 2022-05-12 | Crispr Therapeutics Ag | Manufacturing process for making T cells expressing chimeric antigen receptors |
| JP7456075B2 (ja) * | 2020-01-03 | 2024-03-27 | ビオシオン インコーポレイテッド | 抗体結合ｂｃｍａ及びその使用 |
| CN113248611B (zh) * | 2020-02-13 | 2026-02-06 | 上海泰槿生物技术有限公司 | 抗bcma抗体、其药物组合物及应用 |
| WO2021195362A1 (en) | 2020-03-26 | 2021-09-30 | Seagen Inc. | Methods of treating multiple myeloma |
| WO2021190564A1 (zh) * | 2020-03-26 | 2021-09-30 | 上海翰森生物医药科技有限公司 | 抗体药物偶联物及其医药用途 |
| AU2021251875A1 (en) | 2020-04-10 | 2022-11-03 | Seagen Inc. | Charge variant linkers |
| TW202233248A (zh) | 2020-11-08 | 2022-09-01 | 美商西健公司 | 組合療法 |
| JP2024510435A (ja) | 2021-03-18 | 2024-03-07 | シージェン インコーポレイテッド | 生体活性化合物の内部移行複合体からの選択的薬物放出 |
| CA3212610A1 (en) | 2021-04-20 | 2022-10-27 | Philip MOQUIST | Modulation of antibody-dependent cellular cytotoxicity |
| IL308795A (en) | 2021-05-28 | 2024-01-01 | Seagen Inc | Anthracycline antibody conjugates |
| WO2023016564A1 (zh) | 2021-08-12 | 2023-02-16 | 上海才致药成生物科技有限公司 | 靶向GPC3的抗体干扰素α融合蛋白及其用途 |
| CN116745325A (zh) * | 2021-08-16 | 2023-09-12 | 上海优替济生生物医药有限公司 | Bcma靶向抗体、嵌合抗原受体及其应用 |
| TW202327650A (zh) | 2021-09-23 | 2023-07-16 | 美商思進公司 | 治療多發性骨髓瘤之方法 |
| CN118159563A (zh) * | 2021-10-27 | 2024-06-07 | 詹森生物科技公司 | 用于人和猴组织中的增强型bcma免疫组织化学检测的方法 |
| CN116333134A (zh) * | 2021-12-22 | 2023-06-27 | 上海君实生物医药科技股份有限公司 | 抗bcma抗体及其用途 |
| KR20250004952A (ko) | 2022-03-17 | 2025-01-08 | 씨젠 인크. | 캄프토테신 접합체 |
| CN117126856A (zh) * | 2022-05-20 | 2023-11-28 | 上海雅科生物科技有限公司 | 以bcma胞外结构域为标记的基因、多肽、重组表达载体、基因工程化细胞及其应用 |
| WO2024129756A1 (en) | 2022-12-13 | 2024-06-20 | Seagen Inc. | Site-specific engineered cysteine antibody drug conjugates |
| EP4719352A1 (en) | 2023-05-31 | 2026-04-08 | Capstan Therapeutics, Inc. | Lipid nanoparticle formulations and compositions |
| CN119548619A (zh) * | 2023-08-10 | 2025-03-04 | 亘喜生物科技（上海）有限公司 | 一种双靶点car-t细胞在治疗系统性红斑狼疮及其他b细胞自身免疫病中的用途 |
| US20250127728A1 (en) | 2023-10-05 | 2025-04-24 | Capstan Therapeutics, Inc. | Constrained Ionizable Cationic Lipids and Lipid Nanoparticles |
| WO2025076113A1 (en) | 2023-10-05 | 2025-04-10 | Capstan Therapeutics, Inc. | Ionizable cationic lipids with conserved spacing and lipid nanoparticles |
| TW202535940A (zh) | 2023-10-24 | 2025-09-16 | 美商思進公司 | 化學治療化合物及使用方法 |
| WO2025149947A1 (en) | 2024-01-12 | 2025-07-17 | Seagen Inc. | Antibody-drug conjugates |
| US20250242056A1 (en) | 2024-01-26 | 2025-07-31 | Regeneron Pharmaceuticals, Inc. | Methods and compositions for using plasma cell depleting agents and/or b cell depleting agents to suppress host anti-aav antibody response and enable aav transduction and re-dosing |
| WO2025160340A2 (en) | 2024-01-26 | 2025-07-31 | Regeneron Pharmaceuticals, Inc. | Combination immunosuppression for inhibiting an immune response and enabling immunogen administration and re-administration |
| WO2025184567A1 (en) | 2024-03-01 | 2025-09-04 | Regeneron Pharmaceuticals, Inc. | Methods and compositions for re-dosing aav using anti-cd40 antagonistic antibody to suppress host anti-aav antibody response |
| WO2025217454A2 (en) | 2024-04-11 | 2025-10-16 | Capstan Therapeutics, Inc. | Ionizable cationic lipids and lipid nanoparticles |
| WO2025217452A1 (en) | 2024-04-11 | 2025-10-16 | Capstan Therapeutics, Inc. | Constrained ionizable cationic lipids and lipid nanoparticles |
| WO2026151982A1 (en) | 2025-01-10 | 2026-07-16 | Regeneron Pharmaceuticals, Inc. | Methods of treating food allergy by administering an il-4r antagonist and a bcma targeting agent |
Family Cites Families (65)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4816567A (en) | 1983-04-08 | 1989-03-28 | Genentech, Inc. | Recombinant immunoglobin preparations |
| US5225539A (en) | 1986-03-27 | 1993-07-06 | Medical Research Council | Recombinant altered antibodies and methods of making altered antibodies |
| JP3101690B2 (ja) | 1987-03-18 | 2000-10-23 | エス・ビィ・２・インコーポレイテッド | 変性抗体の、または変性抗体に関する改良 |
| US5047335A (en) | 1988-12-21 | 1991-09-10 | The Regents Of The University Of Calif. | Process for controlling intracellular glycosylation of proteins |
| US5530101A (en) | 1988-12-28 | 1996-06-25 | Protein Design Labs, Inc. | Humanized immunoglobulins |
| US5859205A (en) | 1989-12-21 | 1999-01-12 | Celltech Limited | Humanised antibodies |
| US5278299A (en) | 1991-03-18 | 1994-01-11 | Scripps Clinic And Research Foundation | Method and composition for synthesizing sialylated glycosyl compounds |
| EP0590058B1 (en) | 1991-06-14 | 2003-11-26 | Genentech, Inc. | HUMANIZED Heregulin ANTIBODy |
| WO1993010260A1 (en) | 1991-11-21 | 1993-05-27 | The Board Of Trustees Of The Leland Stanford Junior University | Controlling degradation of glycoprotein oligosaccharides by extracellular glycosisases |
| US5834597A (en) | 1996-05-20 | 1998-11-10 | Protein Design Labs, Inc. | Mutated nonactivating IgG2 domains and anti CD3 antibodies incorporating the same |
| MY128897A (en) | 1999-02-05 | 2007-02-28 | Samsung Electronics Co Ltd | Image texture retrieving method and apparatus thereof |
| HK1043608B (en) | 1999-08-17 | 2007-12-07 | Biogen Ma Inc. | Baff receptor (bcma), an immunoregulatory agent |
| UA74798C2 (uk) | 1999-10-06 | 2006-02-15 | Байоджен Айдек Ма Інк. | Спосіб лікування раку у ссавця за допомогою поліпептиду, що протидіє взаємодії april з його рецепторами |
| US20040002068A1 (en) | 2000-03-01 | 2004-01-01 | Corixa Corporation | Compositions and methods for the detection, diagnosis and therapy of hematological malignancies |
| AU2001268427B2 (en) | 2000-06-16 | 2007-03-29 | Glaxosmithkline Intellectual Property Limited | Antibodies that immunospecifically bind to blys |
| AU2002368077B2 (en) | 2001-07-12 | 2010-03-04 | Jefferson Foote | Super humanized antibodies |
| AU2002356858A1 (en) | 2001-10-24 | 2003-05-06 | National Jewish Medical And Research Center | Structure of tall-1 and its cognate receptor |
| AU2003221256A1 (en) * | 2002-02-21 | 2003-09-09 | Biogen Idec Ma Inc. | Use of bcma as an immunoregulatory agent |
| ES2369542T3 (es) | 2002-07-31 | 2011-12-01 | Seattle Genetics, Inc. | Conjugados de auristatina y su uso para tratar cáncer, una enfermedad autoinmune o una enfermedad infecciosa. |
| ES2605443T3 (es) | 2003-11-06 | 2017-03-14 | Seattle Genetics, Inc. | Conjugados de auristatina con anticuerpos anti-HER2 o anti-CD22 y su uso en terapia |
| WO2005075511A1 (en) | 2004-01-29 | 2005-08-18 | Genentech, Inc. | Variants of the extracellular domain of bcma and uses thereof |
| AU2005290250A1 (en) | 2004-07-30 | 2006-04-06 | Rinat Neuroscience Corp. | Antibodies directed against amyloid-beta peptide and methods using same |
| TR201808537T4 (tr) | 2004-09-23 | 2018-07-23 | Genentech Inc | Sistein değiştirilmiş antikorlar ve konjugatlar. |
| WO2007008848A2 (en) | 2005-07-07 | 2007-01-18 | Seattle Genetics, Inc. | Monomethylvaline compounds having phenylalanine carboxy modifications at the c-terminus |
| ES2708763T3 (es) | 2005-07-07 | 2019-04-11 | Seattle Genetics Inc | Compuestos de monometilvalina que tienen modificaciones de la cadena lateral de fenilalanina en el extremo C |
| CA2629306A1 (en) | 2005-11-23 | 2007-05-31 | Genentech, Inc. | Methods and compositions related to b cell assays |
| PL2099823T5 (pl) | 2006-12-01 | 2023-02-20 | Seagen Inc. | Wariant środków wiążących cel i jego zastosowania |
| CN101903403B (zh) | 2007-10-19 | 2016-03-16 | 西雅图基因公司 | Cd19结合剂及其应用 |
| PL2282773T3 (pl) | 2008-05-02 | 2014-08-29 | Seattle Genetics Inc | Sposoby i kompozycje do wytwarzania przeciwciał i pochodnych przeciwciał o obniżonej fukozylacji rdzeniowej |
| CN102421801B (zh) * | 2009-03-10 | 2016-03-16 | 比奥根Ma公司 | 抗-bcma抗体 |
| EP2488200A4 (en) | 2009-10-14 | 2013-06-12 | Merck Sharp & Dohme | APRIL ANTAGONISTS AND METHOD FOR THEIR USE |
| CN103068405A (zh) | 2010-04-15 | 2013-04-24 | 西雅图基因公司 | 靶向吡咯并苯并二氮杂卓结合物 |
| EP3974453A3 (en) | 2010-11-16 | 2022-08-03 | Amgen Inc. | Agents and methods for treating diseases that correlate with bcma expression |
| PT3156420T (pt) | 2010-12-06 | 2019-05-27 | Seattle Genetics Inc | Anticorpos humanizados a liv-1 e seu uso para tratar o cancro |
| WO2012118622A1 (en) | 2011-02-19 | 2012-09-07 | Baylor Research Institute | Diagnostic and therapeutic uses for b cell maturation antigen |
| RU2623161C2 (ru) | 2011-04-15 | 2017-06-22 | Компуджен Лтд. | Полипептиды и полинуклеотиды и их применение для лечения иммунологических нарушений и рака |
| US20130101599A1 (en) | 2011-04-21 | 2013-04-25 | Boehringer Ingelheim International Gmbh | Bcma-based stratification and therapy for multiple myeloma patients |
| EP2714737A1 (en) * | 2011-05-27 | 2014-04-09 | Glaxo Group Limited | Bcma (cd269/tnfrsf17) -binding proteins |
| KR101412875B1 (ko) | 2012-10-04 | 2014-07-02 | 삼성전기주식회사 | 게이트 구동 회로 및 이를 갖는 인버터 |
| EP2914628A1 (en) * | 2012-11-01 | 2015-09-09 | Max-Delbrück-Centrum für Molekulare Medizin | An antibody that binds cd269 (bcma) suitable for use in the treatment of plasma cell diseases such as multiple myeloma and autoimmune diseases |
| JP6061378B2 (ja) * | 2012-11-05 | 2017-01-18 | 株式会社Ｓｃｒｅｅｎホールディングス | 基板処理装置 |
| TW201425336A (zh) * | 2012-12-07 | 2014-07-01 | Amgen Inc | Ｂｃｍａ抗原結合蛋白質 |
| JP6636803B2 (ja) * | 2013-02-05 | 2020-01-29 | エンクマフ エスアーエールエル | Ｂｃｍａに対する抗体の選択のための方法 |
| AR095374A1 (es) | 2013-03-15 | 2015-10-14 | Amgen Res Munich Gmbh | Moléculas de unión para bcma y cd3 |
| US9688767B2 (en) | 2013-03-15 | 2017-06-27 | Institut National De La Sante Et De La Recherche Medicale (Inserm) | Method of predicting survival time in myocardial infarction patients by measuring BAFF levels |
| EP3131927B8 (en) * | 2014-04-14 | 2020-12-23 | Cellectis | Bcma (cd269) specific chimeric antigen receptors for cancer immunotherapy |
| BR112016024546A2 (pt) * | 2014-04-30 | 2018-01-23 | Max-Delbrück-Centrum Für Molekulare Medizin In Der Helmholtz-Gemeinschaft | anticorpo ou fragmento de anticorpo, anticorpo ou fragmento de anticorpo isolado, conjugado de anticorpo-fármaco, molécula de ácido nucleico, célula hospedeira, e, composição farmacêutica |
| EP2982692A1 (en) | 2014-08-04 | 2016-02-10 | EngMab AG | Bispecific antibodies against CD3epsilon and BCMA |
| US20190209704A1 (en) | 2014-10-20 | 2019-07-11 | Igenica Biotherapeutics, Inc. | Novel antibody-drug conjugates and related compounds, compositions and methods of use |
| BR112017008959A2 (pt) | 2014-10-29 | 2018-01-16 | Seattle Genetics, Inc. | método para tratamento de uma doença. |
| EP3023437A1 (en) | 2014-11-20 | 2016-05-25 | EngMab AG | Bispecific antibodies against CD3epsilon and BCMA |
| ES2808853T3 (es) | 2014-11-20 | 2021-03-02 | Hoffmann La Roche | Cadenas ligeras comunes y procedimientos de uso |
| HRP20210582T1 (hr) | 2014-12-05 | 2021-09-03 | Memorial Sloan Kettering Cancer Center | Antitijela koja ciljaju antigen sazrijevanja b-stanice i postupci uporabe |
| HUE057285T2 (hu) | 2015-04-13 | 2022-04-28 | Pfizer | Terápiás ellenanyagok és alkalmazásaik |
| DK3447075T3 (da) | 2015-05-15 | 2023-11-13 | Massachusetts Gen Hospital | Antagonistiske antistoffer af antitumornekrosefaktorreceptor-superfamilien |
| CA2992797A1 (en) | 2015-08-03 | 2017-02-09 | Engmab Sarl | Monoclonal antibodies against bcma |
| CN105384825B (zh) | 2015-08-11 | 2018-06-01 | 南京传奇生物科技有限公司 | 一种基于单域抗体的双特异性嵌合抗原受体及其应用 |
| TWI811023B (zh) | 2015-08-17 | 2023-08-01 | 美商健生生物科技公司 | 抗bcma抗體，結合bcma及cd3之雙特異性抗原結合分子及其用途 |
| JP6901493B2 (ja) | 2015-11-13 | 2021-07-14 | アメリカ合衆国 | 抗ｂｃｍａポリペプチド及びタンパク質 |
| ES2913208T3 (es) | 2015-12-01 | 2022-06-01 | Glaxosmithkline Ip Dev Ltd | Tratamientos de combinación y usos y métodos de los mismos |
| UA126657C2 (uk) | 2016-02-03 | 2023-01-11 | Емджен Рісерч (Мюнік) Ґмбг | ОДНОЛАНЦЮГОВА КОНСТРУКЦІЯ АНТИТІЛА ДО BCMA І CD3<font face="Symbol">e</font> |
| MA44254A (fr) | 2016-02-17 | 2018-12-26 | Seattle Genetics Inc | Anticorps bcma et leur utilisation pour traiter le cancer et les troubles immunologiques |
| NZ746700A (en) | 2016-04-01 | 2023-04-28 | Kite Pharma Inc | Bcma binding molecules and methods of use thereof |
| AU2018222741A1 (en) * | 2017-02-17 | 2019-09-26 | Unum Therapeutics Inc. | Co-use of anti-BCMA antibody and antibody-coupled T celll receptor (ACTR) in cancer therapy and B cell disorders |
| WO2021195362A1 (en) * | 2020-03-26 | 2021-09-30 | Seagen Inc. | Methods of treating multiple myeloma |
-
2017
- 2017-02-16 MA MA044254A patent/MA44254A/fr unknown
- 2017-02-16 IL IL260732A patent/IL260732B2/en unknown
- 2017-02-16 HK HK19101575.0A patent/HK1259075A1/zh unknown
- 2017-02-16 KR KR1020187021211A patent/KR102816905B1/ko active Active
- 2017-02-16 SG SG10202007836WA patent/SG10202007836WA/en unknown
- 2017-02-16 CN CN201780011604.8A patent/CN108778329B/zh active Active
- 2017-02-16 WO PCT/US2017/018177 patent/WO2017143069A1/en not_active Ceased
- 2017-02-16 SG SG11201806261XA patent/SG11201806261XA/en unknown
- 2017-02-16 CN CN202211055564.6A patent/CN116063503A/zh active Pending
- 2017-02-16 EP EP17753839.4A patent/EP3416687A4/en active Pending
- 2017-02-16 AU AU2017219747A patent/AU2017219747B2/en active Active
- 2017-02-16 JP JP2018543153A patent/JP7152309B2/ja active Active
- 2017-02-16 MX MX2018009700A patent/MX2018009700A/es unknown
- 2017-02-16 US US15/434,921 patent/US20170233484A1/en not_active Abandoned
- 2017-02-16 IL IL311107A patent/IL311107A/en unknown
- 2017-02-16 CA CA3011900A patent/CA3011900A1/en active Pending
- 2017-02-16 BR BR112018016697-9A patent/BR112018016697A2/en unknown
- 2017-02-16 US US15/999,346 patent/US20190194338A1/en not_active Abandoned
-
2018
- 2018-08-09 MX MX2023000889A patent/MX2023000889A/es unknown
- 2018-10-03 US US16/151,012 patent/US20190023801A1/en not_active Abandoned
-
2019
- 2019-05-14 US US16/411,867 patent/US11078291B2/en active Active
-
2020
- 2020-02-17 JP JP2020024261A patent/JP2020073605A/ja active Pending
-
2021
- 2021-06-25 US US17/358,642 patent/US11767365B2/en active Active
-
2022
- 2022-03-01 JP JP2022030779A patent/JP2022069488A/ja not_active Withdrawn
-
2023
- 2023-08-15 US US18/449,876 patent/US20240109975A1/en not_active Abandoned
- 2023-12-14 AU AU2023282281A patent/AU2023282281A1/en active Pending
- 2023-12-22 JP JP2023216464A patent/JP2024019677A/ja active Pending
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| US20260124298A1 (en) | Clec9a binding agents | |
| KR102236259B1 (ko) | 항-lag-3 항체 및 그것의 사용 | |
| AU2014342182B2 (en) | Methods for enhancing immunosuppressive therapy by multiple administration of alpha beta TCR -binding polypeptide | |
| KR101739620B1 (ko) | 특히, 대숙주성 이식편병(gvhd)을 예방하기 위한 항 cd4 항체 | |
| JP2008516970A5 (enExample) | ||
| JP2021516976A5 (enExample) | ||
| RU2013130609A (ru) | Гуманизированные антитела к liv-1 и их применение для лечения рака | |
| JP2021515566A5 (enExample) | ||
| EP2703011A3 (en) | Anti-icos antibodies and their use in treatment of oncology, transplantation and autoimmune disease | |
| JP2021516975A5 (enExample) | ||
| JP2020515247A5 (enExample) | ||
| JP2018506277A5 (enExample) | ||
| JP2014506120A5 (enExample) | ||
| JP2016513467A5 (enExample) | ||
| KR20080047540A (ko) | Ｃｄ20 특이적 결합 분자의 단회 투여 용도 | |
| CN121064331A (zh) | 抗btla抗体 | |
| WO2019032662A1 (en) | CLEC9A BINDING AGENTS AND USES THEREOF | |
| KR20230030632A (ko) | 항-cd70 항체 및 이의 적용 | |
| JP2020523038A5 (enExample) | ||
| JP2013509158A5 (enExample) | ||
| RU2014108815A (ru) | Новые антитела к фосфорилхолину | |
| EP3599250A1 (en) | Antibody conjugate, and related pharmaceutical composition and application | |
| US20250101104A1 (en) | Bispecific molecule with tunable affinity to a targeted antigen | |
| JP2024543385A5 (enExample) | ||
| JP2023539453A5 (enExample) |